Jessica Thomes-Pepin

Lipid Desaturation Is a Metabolic Marker and Therapeutic Target of Ovarian Cancer Stem Cells

Junjie Li, Salvatore Condello, Jessica Thomes-Pepin et al. · Cell stem cell · 2016 · 598 citations · Full text

Life Sciences, Cell Biology, Oncology +17

Atezolizumab, Bevacizumab, and Chemotherapy for Newly Diagnosed Stage III or IV Ovarian Cancer: Placebo-Controlled Randomized Phase III Trial (IMagyn050/GOG 3015/ENGOT-OV39)

Kathleen N. Moore, Michael A. Bookman, Jalid Sehouli et al. · Journal of Clinical Oncology · 2021 · 406 citations · Full text

Medicine, Oncology, Pharmacotherapy +17

Durvalumab Plus Carboplatin/Paclitaxel Followed by Maintenance Durvalumab With or Without Olaparib as First-Line Treatment for Advanced Endometrial Cancer: The Phase III DUO-E Trial

Shannon N. Westin, Kathleen N. Moore, Hye Sook Chon et al. · Journal of Clinical Oncology · 2023 · 331 citations · Full text

Medicine, Oncology, Pharmacology +12

LBA31 Primary results from IMagyn050/GOG 3015/ENGOT-OV39, a double-blind placebo (pbo)-controlled randomised phase III trial of bevacizumab (bev)-containing therapy +/- atezolizumab (atezo) for newly diagnosed stage III/IV ovarian cancer (OC)

Kathleen N. Moore, Michael A. Bookman, Jalid Sehouli et al. · Annals of Oncology · 2020 · 36 citations

Medicine, Gynecology, Oncology +10

Overall survival and patient-reported outcome results from the placebo-controlled randomized phase III IMagyn050/GOG 3015/ENGOT-OV39 trial of atezolizumab for newly diagnosed stage III/IV ovarian cancer

Sandro Pignata, Michael A. Bookman, Jalid Sehouli et al. · Gynecologic Oncology · 2023 · 27 citations · Full text

Medicine, Oncology, Pharmacotherapy +14